Concepts (158)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Glioma | 8 | 2014 | 508 | 1.310 |
Why?
|
| Sleep | 3 | 2025 | 366 | 1.230 |
Why?
|
| Chloride Channels | 4 | 2013 | 56 | 1.110 |
Why?
|
| Developmental Disabilities | 2 | 2025 | 775 | 1.080 |
Why?
|
| Blood-Brain Barrier | 2 | 2019 | 154 | 0.950 |
Why?
|
| ARNTL Transcription Factors | 1 | 2025 | 46 | 0.900 |
Why?
|
| Sleep Deprivation | 1 | 2025 | 43 | 0.890 |
Why?
|
| Dynamins | 1 | 2022 | 45 | 0.750 |
Why?
|
| Epileptic Syndromes | 1 | 2022 | 35 | 0.740 |
Why?
|
| Neurodevelopmental Disorders | 2 | 2025 | 624 | 0.730 |
Why?
|
| Circadian Rhythm | 2 | 2025 | 316 | 0.680 |
Why?
|
| Seizures | 2 | 2025 | 874 | 0.660 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 2 | 2011 | 139 | 0.620 |
Why?
|
| Brain Diseases | 1 | 2022 | 298 | 0.620 |
Why?
|
| Autism Spectrum Disorder | 1 | 2025 | 445 | 0.610 |
Why?
|
| Craniosynostoses | 1 | 2021 | 146 | 0.570 |
Why?
|
| Chlorides | 3 | 2012 | 97 | 0.540 |
Why?
|
| Intellectual Disability | 2 | 2023 | 1080 | 0.530 |
Why?
|
| Repressor Proteins | 1 | 2021 | 760 | 0.490 |
Why?
|
| Intermediate-Conductance Calcium-Activated Potassium Channels | 2 | 2013 | 15 | 0.480 |
Why?
|
| Brain Neoplasms | 4 | 2014 | 1320 | 0.470 |
Why?
|
| Hemimegalencephaly | 1 | 2015 | 1 | 0.460 |
Why?
|
| Rett Syndrome | 2 | 2018 | 229 | 0.450 |
Why?
|
| Methyl-CpG-Binding Protein 2 | 2 | 2018 | 284 | 0.450 |
Why?
|
| Hemispherectomy | 1 | 2015 | 28 | 0.450 |
Why?
|
| Neoplasm Invasiveness | 3 | 2014 | 625 | 0.440 |
Why?
|
| Brain | 3 | 2025 | 3160 | 0.400 |
Why?
|
| Tuberous Sclerosis | 1 | 2015 | 146 | 0.400 |
Why?
|
| Bradykinin | 1 | 2013 | 42 | 0.390 |
Why?
|
| TRPC Cation Channels | 1 | 2012 | 20 | 0.380 |
Why?
|
| Chemotaxis | 1 | 2013 | 61 | 0.380 |
Why?
|
| Ion Channels | 2 | 2011 | 198 | 0.380 |
Why?
|
| Cell Movement | 2 | 2014 | 868 | 0.340 |
Why?
|
| Drosophila melanogaster | 3 | 2025 | 837 | 0.340 |
Why?
|
| Transcription Factors | 1 | 2021 | 2423 | 0.340 |
Why?
|
| Epilepsy | 3 | 2026 | 862 | 0.340 |
Why?
|
| Mitosis | 1 | 2011 | 192 | 0.330 |
Why?
|
| Drosophila Proteins | 3 | 2025 | 776 | 0.320 |
Why?
|
| Mutation | 4 | 2025 | 6088 | 0.310 |
Why?
|
| Membrane Transport Proteins | 1 | 2011 | 177 | 0.310 |
Why?
|
| Verbal Behavior | 1 | 2009 | 44 | 0.290 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2010 | 242 | 0.290 |
Why?
|
| Calcium | 2 | 2012 | 1029 | 0.280 |
Why?
|
| Exons | 2 | 2022 | 762 | 0.280 |
Why?
|
| Reading | 1 | 2009 | 75 | 0.270 |
Why?
|
| Feedback | 1 | 2009 | 147 | 0.270 |
Why?
|
| Potassium Channels, Inwardly Rectifying | 2 | 2018 | 36 | 0.260 |
Why?
|
| Animals | 12 | 2025 | 33781 | 0.250 |
Why?
|
| Receptor, Serotonin, 5-HT1A | 1 | 2025 | 6 | 0.230 |
Why?
|
| Patch-Clamp Techniques | 3 | 2025 | 272 | 0.230 |
Why?
|
| Period Circadian Proteins | 1 | 2025 | 25 | 0.230 |
Why?
|
| Shal Potassium Channels | 1 | 2025 | 48 | 0.230 |
Why?
|
| Optogenetics | 1 | 2025 | 72 | 0.220 |
Why?
|
| Humans | 21 | 2026 | 130262 | 0.210 |
Why?
|
| Gene Expression Regulation | 3 | 2018 | 2338 | 0.210 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2026 | 3396 | 0.210 |
Why?
|
| Homeostasis | 2 | 2025 | 714 | 0.210 |
Why?
|
| Male | 13 | 2026 | 64355 | 0.200 |
Why?
|
| Epilepsy, Absence | 1 | 2023 | 31 | 0.200 |
Why?
|
| Haploinsufficiency | 1 | 2025 | 264 | 0.200 |
Why?
|
| Epilepsy, Generalized | 1 | 2023 | 61 | 0.200 |
Why?
|
| Genetic Association Studies | 2 | 2019 | 817 | 0.190 |
Why?
|
| Causality | 1 | 2022 | 90 | 0.190 |
Why?
|
| Phenotype | 3 | 2023 | 4465 | 0.180 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2010 | 2009 | 0.180 |
Why?
|
| Cell Line, Tumor | 5 | 2013 | 3707 | 0.180 |
Why?
|
| Neuroglia | 1 | 2024 | 223 | 0.180 |
Why?
|
| Infant | 5 | 2026 | 13230 | 0.170 |
Why?
|
| Young Adult | 5 | 2026 | 9993 | 0.170 |
Why?
|
| Heterozygote | 1 | 2022 | 720 | 0.160 |
Why?
|
| Child | 6 | 2026 | 26079 | 0.160 |
Why?
|
| Muscle Hypotonia | 1 | 2021 | 194 | 0.160 |
Why?
|
| Capillary Permeability | 1 | 2019 | 73 | 0.150 |
Why?
|
| Genetic Testing | 1 | 2026 | 1098 | 0.150 |
Why?
|
| CREB-Binding Protein | 1 | 2019 | 55 | 0.150 |
Why?
|
| Endocytosis | 1 | 2019 | 124 | 0.140 |
Why?
|
| Adolescent | 6 | 2026 | 20711 | 0.140 |
Why?
|
| Microcephaly | 1 | 2021 | 348 | 0.140 |
Why?
|
| Child, Preschool | 5 | 2026 | 14939 | 0.140 |
Why?
|
| Parkinson Disease | 1 | 2025 | 725 | 0.130 |
Why?
|
| Neoplasms | 1 | 2011 | 2952 | 0.120 |
Why?
|
| Female | 8 | 2026 | 70269 | 0.120 |
Why?
|
| Central Nervous System Diseases | 1 | 2016 | 97 | 0.110 |
Why?
|
| Astrocytes | 1 | 2018 | 276 | 0.110 |
Why?
|
| Disease Models, Animal | 1 | 2025 | 4661 | 0.110 |
Why?
|
| Mutation, Missense | 1 | 2019 | 922 | 0.110 |
Why?
|
| Cell Size | 2 | 2011 | 80 | 0.110 |
Why?
|
| Receptors, GABA-A | 1 | 2014 | 60 | 0.110 |
Why?
|
| Adult | 5 | 2026 | 31097 | 0.100 |
Why?
|
| Central Nervous System | 1 | 2016 | 274 | 0.100 |
Why?
|
| Symporters | 1 | 2014 | 80 | 0.100 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2014 | 175 | 0.100 |
Why?
|
| Positron-Emission Tomography | 1 | 2015 | 288 | 0.100 |
Why?
|
| Status Epilepticus | 1 | 2015 | 158 | 0.100 |
Why?
|
| Electric Conductivity | 1 | 2012 | 80 | 0.100 |
Why?
|
| Large-Conductance Calcium-Activated Potassium Channels | 1 | 2012 | 22 | 0.090 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2015 | 486 | 0.090 |
Why?
|
| Osmotic Pressure | 1 | 2011 | 24 | 0.090 |
Why?
|
| Cell Shape | 1 | 2011 | 68 | 0.090 |
Why?
|
| Blotting, Western | 1 | 2013 | 1017 | 0.080 |
Why?
|
| Cytoskeleton | 1 | 2011 | 166 | 0.080 |
Why?
|
| Gene Knockdown Techniques | 1 | 2011 | 382 | 0.080 |
Why?
|
| Cell Division | 1 | 2011 | 718 | 0.080 |
Why?
|
| Drosophila | 2 | 2025 | 774 | 0.080 |
Why?
|
| Immunoprecipitation | 1 | 2010 | 190 | 0.080 |
Why?
|
| Cell Membrane | 1 | 2011 | 450 | 0.070 |
Why?
|
| Electrophysiology | 1 | 2010 | 249 | 0.070 |
Why?
|
| Immunohistochemistry | 1 | 2013 | 1594 | 0.070 |
Why?
|
| Calcium Signaling | 1 | 2011 | 247 | 0.070 |
Why?
|
| Cell Cycle | 1 | 2011 | 597 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2019 | 3746 | 0.070 |
Why?
|
| Peptides | 1 | 2010 | 705 | 0.060 |
Why?
|
| Phosphorylation | 1 | 2010 | 1573 | 0.060 |
Why?
|
| Quinidine | 1 | 2025 | 10 | 0.060 |
Why?
|
| Apoptosis | 1 | 2012 | 1829 | 0.060 |
Why?
|
| Cricetulus | 1 | 2025 | 89 | 0.060 |
Why?
|
| CHO Cells | 1 | 2025 | 151 | 0.060 |
Why?
|
| Genotype | 2 | 2023 | 2590 | 0.060 |
Why?
|
| Severity of Illness Index | 1 | 2014 | 3031 | 0.060 |
Why?
|
| Cricetinae | 1 | 2025 | 362 | 0.060 |
Why?
|
| Sex Factors | 1 | 2009 | 1339 | 0.050 |
Why?
|
| Cell Proliferation | 1 | 2011 | 2459 | 0.050 |
Why?
|
| Nuclear Receptor Subfamily 1, Group F, Member 2 | 1 | 2023 | 1 | 0.050 |
Why?
|
| alpha-Synuclein | 1 | 2025 | 141 | 0.050 |
Why?
|
| Pedigree | 1 | 2026 | 1672 | 0.050 |
Why?
|
| Lipids | 1 | 2024 | 560 | 0.040 |
Why?
|
| Neurons | 2 | 2024 | 2001 | 0.040 |
Why?
|
| Treatment Outcome | 1 | 2015 | 12830 | 0.040 |
Why?
|
| Rubinstein-Taybi Syndrome | 1 | 2019 | 16 | 0.040 |
Why?
|
| Facies | 1 | 2019 | 157 | 0.040 |
Why?
|
| Time Factors | 1 | 2009 | 6197 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2025 | 3358 | 0.030 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2019 | 568 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2026 | 5046 | 0.030 |
Why?
|
| Syndrome | 1 | 2019 | 1159 | 0.030 |
Why?
|
| Interneurons | 1 | 2014 | 142 | 0.020 |
Why?
|
| Clotrimazole | 1 | 2012 | 2 | 0.020 |
Why?
|
| Staurosporine | 1 | 2012 | 21 | 0.020 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2012 | 21 | 0.020 |
Why?
|
| Mice | 2 | 2023 | 18195 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2018 | 2331 | 0.020 |
Why?
|
| Potassium Channel Blockers | 1 | 2012 | 84 | 0.020 |
Why?
|
| Synaptic Transmission | 1 | 2014 | 314 | 0.020 |
Why?
|
| Ion Channel Gating | 1 | 2012 | 120 | 0.020 |
Why?
|
| Sodium-Potassium-Chloride Symporters | 1 | 2011 | 6 | 0.020 |
Why?
|
| Solute Carrier Family 12, Member 2 | 1 | 2011 | 4 | 0.020 |
Why?
|
| Bumetanide | 1 | 2011 | 5 | 0.020 |
Why?
|
| WNK Lysine-Deficient Protein Kinase 1 | 1 | 2011 | 15 | 0.020 |
Why?
|
| Potassium | 1 | 2012 | 268 | 0.020 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 1 | 2011 | 28 | 0.020 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 2011 | 38 | 0.020 |
Why?
|
| Risk Factors | 1 | 2025 | 10938 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 2012 | 560 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2011 | 666 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2011 | 584 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2026 | 17500 | 0.020 |
Why?
|
| Aged | 1 | 2025 | 20840 | 0.020 |
Why?
|
| Middle Aged | 1 | 2026 | 28337 | 0.010 |
Why?
|